Skip to main content
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia

PR Newswire - Fri Sep 15, 2023

European Commission Approval Decision Expected Q4 2023

Opinion Based on Positive Results from Global Phase 2 and Ongoing Extension Study 

U.S. Food and Drug Administration PDUFA Target Action Date for Supplemental New Drug Application for VOXZOGO for Children Under 5 is Oct. 21, 2023

Read more at prnewswire.com